Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2

A Multidisciplinary Perspective

Häftad, Engelska, 2024

Av Siguna Mueller

2 109 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Finns i fler format (2)

Inbunden

2 109 kr

Skickas inom 10-15 vardagar

Häftad

799 kr

Skickas inom 7-10 vardagar

This book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy.This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general.

Produktinformation

Utgivningsdatum2024-01-07
Mått155 x 235 x 26 mm
Vikt709 g
FormatHäftad
SpråkEngelska
Antal sidor439
FörlagSpringer International Publishing AG
ISBN9783031189050

Tillhör följande kategorier

Biokemisk teknik inom Naturvetenskap och teknik
Samhällsmedicin och preventiv medicin inom Medicin
Biologi inom Naturvetenskap och teknik
Infektionssjukdomar och smittsamma sjukdomar inom Medicin
Patologi inom Medicin

Siguna Mueller spent the first 20 years of her academic career in mathematics (M.S. in Mathematics and Statistics and Ph.D. in Mathematics, University of Klagenfurt, Austria, both summa cum laude). She was among the first women in Austria to receive the Habilitation in Discrete Mathematics and Cryptography (2002). The following 15 years she spent as a Research Associate at the Centre for Information Security and Cryptography Research, University of Calgary, and as an Assistant Professor at the University of Wyoming. A lifelong passion for biology and medicine eventually triggered her decision to radically expand her field of expertise. Consequently, she earned her second Ph.D. (Biomedical Sciences) in 2014 at the University of Wyoming (with a GPA of 4.0). Since then she has been utilizing her experience in the theoretical fields to help advance a broader appreciation and comprehension of phenomena and challenges arising in the biological and life science domains. For almost ten years, she has been warning of new Biosafety and Public Health dangers, but for years was ignored. Only recently, her concerns about new safety/security challenges in synthetic biology have been supported by others, and she has become one of the leaders in the new field of cyberbiosecurity. Her interests and curiosities are not limited to the above-mentioned disciplines as she finds great excitement in physics, theology, philosophy, ethics, spirituality, and the complexity and fascination of nature altogether. As such, it has been natural for her, employing her multi-disciplinary experience, to appraise the new Covid-19 vaccines, through rigorous, balanced, and scientific logic.

Chapter 1: Introduction.- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience.- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines.- Chapter 3: Relevance for mRNA vaccine safety.- Chapter 4: From Challenges to Opportunities and Open Questions.- Chapter 5: The challenge of evaluating vaccine safety and effectiveness.- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development.- Chapter 7: Scales, pseudoscales, the human factor, and a way forward.- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta.- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection.- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs.- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen.- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion.- Part III: The Omicron variants.- Chapter 12: Omicron.- Chapter 13: Conclusion.

“This book is both impressive and remarkable. … Dr. Mueller has indeed articulated legitimate questions and hypotheses. … The persistence of these attitudes makes this book as remarkable apropos the publisher as it is impressive apropos the author. Accordingly, the academic publishing giant Springer Nature, surely understood that because COVID-19 will be studied and debated for decades, it is essential that a sourcebook … should exist in the mainstream academic literature. … Dr. Mueller’s work takes on greater significance.” (David Wiseman, TS News, trialsitenews.com, May 24, 2024)